Project Funding Details

Lay abstract (no permission to release technical abstract): TGL is formulated to accelerate clinical oncology research through partnership and drive key initiatives: facilitate access to genome-wide multi-omic assays from pathology specimens (Formalin Fixed Paraffin Embedded, FFPE); identify molecular patterns associated with patient outcome and clinical variables from standard of care and second line therapies; share and continuously improve integrated analysis methods Github to facilitate robust tumor phenotypic classification; facilitate actionable mutation detection through an emphasis on multiplatform molecular diagnostics, including methylation, transcriptome and exome sequencing; and facilitate rapid dissemination of patient tumor genomic reports and annotation through cBioPortal unifying genomic interpretation, pathology review and imaging into a common accessible database. TGL participates in clinical trial research through the Princess Margaret Cancer Genomics (CGP) and Tumor Immunotherapy Programs (TIP) providing extended capabilities and infrastructure. TGL is supporting the Ontario-wide Targeted Nucleic Acid Evaluation (OCTANE) Trial, which is increasing cancer patient access to next-generation sequencing (NGS) technology and rapid informatic analysis in therapeutic management. OCTANE is establishing large provincial cohorts of consented patients for NGS-based genomic profiling that may inform the use of approved therapies and identify patients that may benefit from advanced molecular profiling within TGL. TGL participates in a variety of clinical research studies including; Genomic Investigation of Unusual Responders (GENIUS), Integrative Sequencing in Germline and Hereditary Tumors (INSIGHT), Comprehensive Translational Research Study of Head and Neck Tumors, Determinants of Outcome in Medulloblastoma and Ependymoma in Ontario, Accelerated Identification and Validation of Novel Molecular Signatures to Improve Treatment in Early Stage Non-small Cell Lung Cancer Patients, Retrospective Analysis of Cloncal Evolution and Tumor Heterogeneity from IMPACT (REACT), Investigator Initiated Phase II Study of Pembrolizumab Immunological Response Evaluation (INSPIRE), Biallelic Mismatch Repair Deficiency Syndrome (bMMRD), Novel Universal Classification of Childhood Low Grade Gliomas using Clinico-pathological and Molecular Methods, Comprehensive Genomic Characterization of Lung Adenocarcinoma in Never Smokers, Treatment-free Remission Accomplished with Dasatinib in Patients with CML, Molecular Testing of Tumor Samples as a Classification Tool, An Open-label, Phase Basket Study of Hypomethylating Agent Oral Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR), plus many more! TGL prioritizes research-grade lab and computational capabilities to advance, validate and translate robust protocols for integration by clinical laboratories (College of American Pathologist (CAP), Clinical Laboratory Improvement Amendments (CLIA), Ontario Laboratory Accreditation (OLA)) in the Ontario healthcare community.

See Tech Abstract